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The TP53 gene has an important role in the protection of cells from DNA damage due to UV exposure, and
sequence variation in the gene may alter skin cancer susceptibility. To examine the association between the
TP53 Arg72Pro polymorphism and skin cancer risk, we undertook a meta-analysis of 15 case–control studies
involving 6,362 subjects. The quality of the studies was assessed according to a predefined scale. Crude odds
ratios (ORs) with 95% confidence intervals (CIs) were assessed for association using a random-effects model.
Overall, no evidence of association was observed between TP53 genotypes and the risk of skin cancer in any
genetic model (Arg/Arg vs. Pro/Pro: OR¼ 1.05, 95% CI: 0.71–1.55; Arg/Pro vs. Pro/Pro: OR¼ 0.92, 95% CI: 0.68–1.24;
Arg/ArgþArg/Pro vs. Pro/Pro: OR¼ 0.97, 95% CI: 0.70–1.35; Arg/Arg vs. Arg/Proþ Pro/Pro: OR¼ 1.15, 95% CI:
0.91–1.46). Stratified analyses according to ethnicity and quality score of the studies also detected no significant
association in any subgroup. Furthermore, no effect of this polymorphism on subtype of skin cancer, such as
melanoma, squamous cell carcinoma, and basal cell carcinoma, was observed. In conclusion, this meta-analysis
suggests that the TP53 Arg72Pro polymorphism may have little involvement in skin cancer susceptibility.
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INTRODUCTION
Skin cancer is the most frequent cancer in humans, especially
in the Western world (Leiter and Garbe, 2008; Gordon,
2009). Statistics show that one in five Americans (one in three
whites) will develop skin cancer in their lifetime (Gordon,
2009). On the basis of the cell types and tissues affected, skin
cancer has several subtypes, with the main forms being
melanoma and nonmelanoma skin cancers, including squa-
mous cell carcinoma (SCC) and basal cell carcinoma (BCC)
(Mueller and Reichrath, 2008). A large body of epidemio-
logical, experimental, and molecular evidence implicates
UV radiation as an important risk factor for skin cancer
(Young, 2009). In addition, predisposition to skin cancer
is mediated by genetic factors, including both germinal
and somatic alterations as well as genetic polymorphisms
(Tsai and Tsao, 2004; Meyer, 2009). However, the genetic
factors that modify the risk of many skin cancers, particularly
melanoma, SCC, and BCC, have yet to be thoroughly
investigated.
TP53 is a major regulator of the cellular response to stress
and serves as a tumor suppressor by inducing cell-cycle arrest
or apoptosis (Levine et al., 2004). Inactivation of the TP53
signaling pathway has been detected in most human cancers
(Soussi and Wiman, 2007). Polymorphisms of TP53 have
previously been reported to be possible risk factors for several
kinds of tumors (Whibley et al., 2009). The most common
polymorphism of TP53 is at the 72nd amino acid residue,
with an arginine (Arg)-to-proline (Pro) change because
of a G-C transversion (Matlashewski et al., 1987).
Differences in the biochemical or biological characteristics
of these wild-type TP53 variants have been reported (Thomas
et al., 1999). In particular, the Arg72 variant induces
apoptosis markedly more efficiently than the Pro72 variant,
which indicates that the two polymorphic variants of TP53
are functionally distinct, and these differences may influence
cancer risk and treatment (Dumont et al., 2003; Bergamaschi
et al., 2006).
It has been shown that TP53 has an important role in the
protection of cells from DNA damage due to UV exposure
(Benjamin and Ananthaswamy, 2007; Benjamin et al., 2008).
In order to investigate the relationship between sequence
variation of TP53 and skin carcinogenesis, several studies in
recent years have focused on the association between TP53
Arg72Pro polymorphism and skin cancer susceptibility, but
the results are inconclusive (Dokianakis et al., 2000; Marshall
et al., 2000; Bastiaens et al., 2001; O’Connor et al., 2001;
Cairey-Remonnay et al., 2002; McGregor et al., 2002; Chen
et al., 2003; Shen et al., 2003; Gustafsson et al., 2004; de
Oliveira et al., 2004; Gwosdz et al., 2006; Han et al., 2006;
Pezeshki et al., 2006; Bendesky et al., 2007; Queille et al.,
2007; Stefanaki et al., 2007; Li et al., 2008; Nan et al., 2008,
2009). Hence, we performed a meta-analysis of all eligible
studies to derive a more precise estimation of the association
to help us better understand its possible influence on skin
cancer risk.
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RESULTS
Study characteristics
In total, 21 studies were identified through literature search
and selection based on the inclusion criteria. During the
extraction of data, two reports that were not case–control
studies were excluded (Spatz et al., 2001; Firoz et al., 2009).
One study was excluded because of the lack of Arg/Arg,
Arg/Pro, and Pro/Pro genotype data for cases and controls
(Chen et al., 2003). Of the remaining 18 studies, two were
excluded because they were duplications of a previous
publication (Nan et al., 2008, 2009). Two other studies
were conducted by the same research group, and one study
(Li et al., 2008) was an extension of another (Shen et al.,
2003); only the newly published study was included in the
meta-analysis. Ultimately, 15 studies were identified as
eligible and analyzed (Dokianakis et al., 2000; Marshall
et al., 2000; Bastiaens et al., 2001; O’Connor et al., 2001;
Cairey-Remonnay et al., 2002; McGregor et al., 2002;
Gustafsson et al., 2004; de Oliveira et al., 2004; Gwosdz
et al., 2006; Han et al., 2006; Pezeshki et al., 2006; Bendesky
et al., 2007; Queille et al., 2007; Stefanaki et al., 2007;
Li et al., 2008).
The characteristics of these 15 case–control studies are
summarized in Table 1. Most of the studies (12 of 15) were
performed on Caucasians. Of the 15 studies, three focused
only on melanoma (Gwosdz et al., 2006; Stefanaki et al.,
2007; Li et al., 2008), two on SCC (Cairey-Remonnay et al.,
2002; Gustafsson et al., 2004), and one on BCC (Pezeshki
et al., 2006); two studies investigated both SCC and BCC
(McGregor et al., 2002; Bendesky et al., 2007); four
investigated SCC, BCC, and melanoma (Dokianakis et al.,
2000; Marshall et al., 2000; Bastiaens et al., 2001; Han et al.,
2006); two explored nonmelanoma skin cancer, subtype
unspecified (O’Connor et al., 2001; Queille et al., 2007); and
Table 1. Main characteristics of studies included in the meta-analysis
First author
(year) Country Ethnicity
Case
source
Control
source
Tissue
sampled
Tumor type
(number of cases)
Sample size
(case/control)
Quality
score
Dokianakis et al.
(2000)
Greece Caucasian Hospital Unknown Tumor
tissue
BCC (22), SCC (3),
other tumors (4)
27/59 2
Marshall et al.
(2000)
England Caucasian Hospital Hospital Blood SCC (34), other
tumors (11)
55/84 9
Bastiaens et al.
(2001)
The Netherlands Caucasian Hospital Hospital Blood SCC (87), BCC (114),
melanoma (120)
321/157 10
O’Connor et al.
(2001)
Ireland Caucasian Hospital Volunteers Blood NMSC (55) 55/115 7
Cairey-Remonnay
et al. (2002)
France Caucasian Unknown Unknown Tumor
tissue
SCC (70) 70/29 0
McGregor et al.
(2002)
England Caucasian Hospital Hospital Blood SCC (109), BCC (89),
both BCC and SCC (16)
182/156 10
Gustafsson et al.
(2004)
Sweden Caucasian Pathology
archives
Blood donors Normal
tissue
SCC (53) 53/96 9
de Oliveira et al.
(2004)
Brazil Other Hospital Unknown Normal
tissue
Skin cancer with
unknown subtype (16)
16/27 8
Gwosdz et al.
(2006)
Germany Caucasian Hospital Blood donors Blood Melanoma (49) 49/193 11
Han et al.
(2006)
USA Caucasian Population Population Blood SCC (272), BCC (285),
melanoma (201)
758/816 15
Pezeshki et al.
(2006)
Iran Asian Unknown Blood donors Blood BCC (91) 91/465 10
Stefanaki et al.
(2007)
Greece Caucasian Hospital Hospital Blood Melanoma (107) 107/145 10
Bendesky et al.
(2007)
Mexico Other Hospital Hospital Blood SCC (42), BCC (204),
both BCC and SCC (5)
241/238 10
Queille et al.
(2007)
France Caucasian Unknown Unknown Blood NMSC (30) 30/84 6
Li et al.
(2008)
USA Caucasian Hospital Hospital Blood Melanoma (805) 805/838 12
Abbreviations: BCC, basal cell carcinoma; NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma.
Both BCC and SCC belong to NMSC.
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Table 2. Distribution of TP53 Arg72Pro genotypes among skin cancer cases and controls included in the
meta-analysis
Cases (n) Controls (n)
First author (year) Arg/Arg Arg/Pro Pro/Pro Arg/Arg Arg/Pro Pro/Pro
P-value of HWE
in controls
All skin cancers
Dokianakis et al. (2000) 19 5 3 12 41 6 0.002
Marshall et al. (2000) 34 18 3 39 39 6 0.369
Bastiaens et al. (2001) 169 131 21 75 72 10 0.180
O’Connor et al. (2001) 43 11 1 91 20 4 0.045
Cairey-Remonnay et al. (2002) 50 16 4 17 7 5 0.025
McGregor et al. (2002) 124 58 0 85 66 5 0.064
Gustafsson et al. (2004) 30 19 5 62 31 3 0.711
de Oliveira et al. (2004) 16 0 0 16 9 2 0.647
Gwosdz et al. (2006) 18 24 7 114 66 13 0.419
Han et al. (2006) 409 294 55 474 297 45 0.864
Pezeshki et al. (2006) 34 47 10 162 217 86 0.376
Stefanaki et al. (2007) 52 44 11 73 66 6 0.058
Bendesky et al. (2007) 122 94 25 126 94 18 0.935
Queille et al. (2007) 13 15 2 39 39 6 0.369
Li et al. (2008) 465 300 40 432 350 56 0.184
Melanomas
Bastiaens et al. (2001) 65 48 7 75 72 10 0.180
Gwosdz et al. (2006) 18 24 7 114 66 13 0.419
Han et al. (2006) 104 82 15 474 297 45 0.864
Stefanaki et al. (2007) 52 44 11 73 66 6 0.057
Li et al. (2008) 465 300 40 432 350 56 0.184
NMSC
Dokianakis et al. (2000) 19 5 3 12 41 6 0.002
Marshall et al. (2000) 18 14 2 39 39 6 0.369
Bastiaens et al. (2001) 104 83 14 75 72 10 0.180
O’Connor et al. (2001) 43 11 1 91 20 4 0.045
Cairey-Remonnay et al. (2002) 50 16 4 17 7 5 0.025
McGregor et al. (2002) 124 58 0 85 66 5 0.064
Gustafsson et al. (2004) 30 19 5 62 31 3 0.711
Han et al. (2006) 305 212 40 474 297 45 0.864
Pezeshki et al. (2006) 34 47 10 162 217 86 0.376
Bendesky et al. (2007) 122 94 25 126 94 18 0.935
Queille et al. (2007) 13 15 2 39 39 6 0.369
SCC
Dokianakis et al. (2000) 2 1 0 12 41 6 0.002
Marshall et al. (2000) 18 14 2 39 39 6 0.369
Bastiaens et al. (2001) 41 40 6 75 72 10 0.180
Cairey-Remonnay et al. (2002) 50 16 4 17 7 5 0.025
McGregor et al. (2002) 74 35 0 85 66 5 0.064
Table 2 continued on the following page
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one explored skin cancer, pathologic subtype unspecified (de
Oliveira et al., 2004). Sample sizes of the 15 studies ranged
from 43 to 1,643. In total, 2,860 skin cancer cases and 3,502
controls were represented in the meta-analysis. Quality
scores for the individual studies ranged from 0 to 15, with
53% (8 of 15) of the studies being classified as high quality.
Distribution of TP53 Arg72Pro polymorphism genotype
frequencies among skin cancer cases and controls of the 15
studies are shown in Table 2. Noticeably, deviation from
Hardy–Weinberg equilibrium of genotype frequencies among
the controls was detected in three studies (Dokianakis et al.,
2000; O’Connor et al., 2001; Cairey-Remonnay et al., 2002).
The frequencies of heterozygote genotype among the cases of
the studies using tumor tissues to assess TP53 genotypes
(Dokianakis et al., 2000; Cairey-Remonnay et al., 2002) are
obviously lower than those of other studies. This indicates
that loss of heterozygosity may exist. Additionally, in studies
with more than 200 samples, there was not a wide variation
of Arg72 and Pro72 allele frequencies among controls, with
the Arg72 allele frequency ranging from 71 to 76% (Bastiaens
et al., 2001; McGregor et al., 2002; Gwosdz et al., 2006; Han
et al., 2006; Bendesky et al., 2007; Stefanaki et al., 2007;
Li et al., 2008), except for 58% in one study conducted in
Asians (Pezeshki et al., 2006). But in studies with fewer than
200 subjects, the control groups represent a diverse
frequency of the Arg72 allele, which ranges from 55 to
88% (Dokianakis et al., 2000; Marshall et al., 2000;
O’Connor et al., 2001; Cairey-Remonnay et al., 2002;
Gustafsson et al., 2004; de Oliveira et al., 2004; Queille
et al., 2007). This may suggest that small sample size does not
precisely reflect the genotype frequencies of the studied
population.
Meta-analysis results
Overall, when all types of skin cancer were considered
together in the meta-analysis, there was no evidence of a
significant association between the risk of skin cancer and the
variant genotypes of TP53 Arg72Pro polymorphism in any
genetic model (homozygote comparison: odds ratio (OR)¼ 1.
05, 95% confidence interval (CI): 0.71–1.55; heterozygote
comparison: OR¼ 0.92, 95% CI: 0.68–1.24; dominant
model: OR¼0.97, 95% CI: 0.70–1.35; recessive model:
OR¼1.15, 95% CI: 0.91–1.46; Table 3). Nevertheless,
significant between-study heterogeneity was detected in
all genetic models, except for heterozygote comparison
(Table 3).
In order to determine the main reasons for the hetero-
geneity across studies and obtain the exact consequence of
the relationship between TP53 Arg72Pro polymorphism and
skin cancer susceptibility, stratified analyses by ethnicity and
quality score of studies were performed. However, a
significant association between skin cancer risk and TP53
genotype was not found in any subgroup under different
genetic models (Table 3).
Next, we investigated the effect of the TP53 Arg72Pro
polymorphism on the susceptibility to subtypes of skin
cancer. Overall, no evidence of association was observed
in any genetic model between TP53 genotype and risk of
melanoma, nonmelanoma skin cancer, SCC, and BCC
(Table 4). Furthermore, we performed subgroup analyses
according to ethnicity and quality score of the studies for
every subtype of skin cancer, except for melanomas because
all the studies on melanomas were conducted in Caucasians
and classified as high quality. No significant association was
found for any of the subgroups in any genetic model, except
for the subgroup of a study on BCC classified as low quality in
heterozygote comparison (OR¼0.15, 95% CI: 0.02–0.90)
and recessive model (OR¼ 9.79, 95% CI: 3.13–30.60,
Table 4). Because this subgroup contains only one study
with a quality score of only 2, the results may be unreliable
and solid results need to be obtained from better-designed
studies.
Table 2. Continued
Cases (n) Controls (n)
First author (year) Arg/Arg Arg/Pro Pro/Pro Arg/Arg Arg/Pro Pro/Pro
P-value of HWE
in controls
Gustafsson et al. (2004) 30 19 5 62 31 3 0.711
Han et al. (2006) 151 104 17 474 297 45 0.864
Bendesky et al. (2007) 18 21 3 126 94 18 0.935
BCC
Dokianakis et al. (2000) 15 3 3 12 41 6 0.002
Bastiaens et al. (2001) 63 43 8 75 72 10 0.180
McGregor et al. (2002) 66 23 0 85 66 5 0.064
Han et al. (2006) 154 108 23 474 297 45 0.864
Pezeshki et al. (2006) 34 47 10 162 217 86 0.376
Bendesky et al. (2007) 108 74 22 126 94 18 0.935
Abbreviations: BCC, basal cell carcinoma; HWE, Hardy–Weinberg equilibrium; NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma.
www.jidonline.org 223
D-K Jiang et al.
TP53 Arg72Pro Polymorphism and Skin Cancer Risk
Sensitivity analyses
A single study involved in the meta-analysis was deleted each
time to reflect the influence of the individual data set on the
pooled ORs, and most of the corresponding pooled ORs were
not materially altered (data not shown).
Publication bias
Both Begg’s funnel plot and Egger’s test were performed
to assess the publication bias of the literature. The shape of
the funnel plots did not reveal any evidence of obvious
asymmetry for all genetic models in the overall meta-analysis
(Figure 1 shows the funnel plot of overall Arg/Arg vs. Pro/Pro).
Then, Egger’s test was used to provide statistical evidence of
funnel plot symmetry. The results still did not present any
obvious evidence of publication bias for any of the genetic
models (P¼ 0.894 for homozygote comparison, P¼ 0.593 for
heterozygote comparison, P¼ 0.565 for dominant model,
and P¼0.518 for recessive model). Neither Begg’s funnel
plot nor Egger’s test detected any obvious evidence of
publication bias in the subgroup analyses for all genetic
models (data not shown).
DISCUSSION
The TP53 pathway with a core component being a negative
feedback loop between MDM2 and TP53 has been shown to
have a vital role in the protection of cells from DNA damage
due to UV exposure (Tsai and Tsao, 2004). Sequence
variation in the TP53 gene is suggested to alter skin cancer
susceptibility. Since the identification of the TP53 Arg72Pro
polymorphism (Matlashewski et al., 1987), a number of
studies have investigated the genetic effect of the TP53
Arg72Pro polymorphism on skin cancer susceptibility, with
conflicting results (Dokianakis et al., 2000; Marshall et al.,
2000; Bastiaens et al., 2001; O’Connor et al., 2001; Cairey-
Remonnay et al., 2002; McGregor et al., 2002; Chen et al.,
2003; Shen et al., 2003; Gustafsson et al., 2004; de Oliveira
et al., 2004; Gwosdz et al., 2006; Han et al., 2006; Pezeshki
et al., 2006; Bendesky et al., 2007; Queille et al., 2007;
Stefanaki et al., 2007; Li et al., 2008; Nan et al., 2008, 2009).
This led us to undertake the present meta-analysis, in which
quantitative synthesis of all the available data might help us to
separate the true from the false, to explore a more robust
estimate of the effect of TP53 Arg72Pro polymorphism on skin
cancer risk. The main finding of our pooled analysis of 15
published studies encompassing 2,860 cases and 3,502 controls
is that no evidence of significant association was found between
TP53 genotype and the risk of any type of skin cancer.
In clarifying an association between genetic polymorph-
isms and cancer risk, the quality of study design is of great
importance. However, some of the analyzed studies had
methodological shortcomings. For instance, the source and
the selection criteria of case and/or control groups were not
clearly presented in several studies (Dokianakis et al., 2000;
Cairey-Remonnay et al., 2002; de Oliveira et al., 2004;
Queille et al., 2007), leading to possible biases. Also, in two
of the included studies, the specimens used to determine
TP53 genotypes were tumor tissue (Dokianakis et al., 2000;
Cairey-Remonnay et al., 2002), in which loss of hetero-
zygosity is a frequent event (Lea et al., 2007); spurious results
may therefore have been obtained. In addition, genetic
distributions of the controls in three studies deviated from
Hardy–Weinberg equilibrium (Dokianakis et al., 2000;
O’Connor et al., 2001; Cairey-Remonnay et al., 2002),
which may have been the result of genotyping errors or
selection bias in controls and/or population stratification
(Mitchell et al., 2003; Hosking et al., 2004). Regardless of the
causes of disequilibrium, the results of genetic association
studies might be spurious if the controls were not in
Hardy–Weinberg equilibrium (Salanti et al., 2005; Trikalinos
et al., 2006). Some of the studies had a very small sample size
and did not have adequate power to detect the possible risk
for TP53 Arg72Pro polymorphism, and the observed sig-
nificant ORs in these studies may be false associations
(Dokianakis et al., 2000; Marshall et al., 2000; O’Connor
Table 3. Results of meta-analysis for TP53 Arg72Pro polymorphism and the risk of all skin cancers
Arg/Arg
vs. Pro/Pro
Arg/Pro
vs. Pro/Pro
Arg/Arg+Arg/Pro
vs. Pro/Pro
Arg/Arg
vs. Arg/Pro+Pro/Pro
Study
group n1
Sample size
(case/control) OR (95% CI) P-value2 OR (95% CI) P-value2 OR (95% CI) P-value2 OR (95% CI) P-value2
Total 15 2,860/3,502 1.05 (0.71-1.55) 0.005 0.92 (0.68-1.24) 0.154 0.97 (0.70-1.35) 0.046 1.15 (0.91–1.46) o0.001
Ethnicity
Caucasian 12 2,512/2,772 1.01 (0.63–1.62) 0.005 0.87 (0.63–1.20) 0.237 0.92 (0.63–1.35) 0.059 1.16 (0.88–1.53) o0.001
Other3 3 348/730 1.22 (0.51–2.92) 0.108 1.15 (0.45–2.91) 0.059 1.20 (0.53–2.75) 0.109 1.12 (0.63–1.99) 0.080
Quality score
o10 7 306/494 1.59 (0.76–3.34) 0.247 0.86 (0.40–1.86) 0.275 1.20 (0.64–2.25) 0.413 1.73 (0.87–3.42) 0.001
X10 8 2,554/3,008 0.89 (0.57–1.41) 0.003 0.93 (0.67–1.30) 0.112 0.91 (0.61–1.35) 0.015 1.03 (0.82–1.29) 0.001
Abbreviations: CI, confidence interval; OR, odds ratio.
1Number of comparisons.
2P-value of Q-test for heterogeneity test.
3All populations combined, except for Caucasian.
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et al., 2001; Cairey-Remonnay et al., 2002; Gustafsson et al.,
2004; de Oliveira et al., 2004; Queille et al., 2007).
Therefore, in order to evaluate and minimize the potential
for selection bias of cases and controls, inappropriate
materials for assessment of genotype in cases, genotyping
errors, and/or population stratification in controls, as well as
insufficient statistical power, the quality of the individual
studies in our meta-analysis was assessed using a predefined
scale and subgroup analyses were performed according to a
quality score of the study, although no validated quality
scoring system currently exists (Sanderson et al., 2007) and
our quality scale evidently had a subjective component.
Nevertheless, no effect of this polymorphism on skin cancer
overall or subtypes was observed when the analysis was
restricted to high-quality studies.
The different capabilities of the two polymorphic variants
of the TP53 Arg72Pro polymorphism in binding transcrip-
tional proteins, activating transcription, and suppressing
transformation of some primary cells have been reported
(Chang et al., 2002). In particular, the Arg72 variant has a
greater ability to localize in the mitochondria to regulate the
release of cytochrome c, which has an important role in
apoptosis (Dumont et al., 2003). Moreover, inhibitor of
apoptosis stimulating protein of p53 (iASPP), which is one of
the most evolutionarily conserved inhibitors of TP53, binds to
and regulates the activity of Arg72 less efficiently than that of
Pro72 (Bergamaschi et al., 2006). Thus, the Arg72 variant
induces apoptosis markedly more efficiently than does the
Pro72 variant. On the other hand, a high frequency of TP53
mutation, leading to dysfunctional TP53 protein and lose of
Table 4. Results of meta-analysis for TP53 Arg72Pro polymorphism and the risk of subtypes of skin cancers
Arg/Arg
vs. Pro/Pro
Arg/Pro
vs. Pro/Pro
Arg/Arg+Arg/Pro
vs. Pro/Pro
Arg/Arg
vs. Arg/Pro+Pro/Pro
Study
group n1
Sample size
(case/control) OR (95% CI) P-value2 OR (95% CI) P-value2 OR (95% CI) P-value2 OR (95% CI) P-value2
Melanomas 5 1,282/2,149 0.73 (0.39–1.38) 0.008 0.88 (0.62–1.27) 0.307 0.78 (0.47–1.30) 0.052 0.91 (0.64–1.30) 0.002
NMSC 11 1,541/2,299 1.15 (0.74–1.78) 0.065 0.96 (0.66–1.41) 0.196 1.04 (0.71–1.52) 0.150 1.20 (0.91–1.57) 0.001
Ethnicity
Caucasian 9 1,209/1,596 1.22 (0.68–2.16) 0.085 0.88 (0.57–1.36) 0.326 0.99 (0.63–1.56) 0.256 1.29 (0.90–1.85) o0.001
Other3 2 332/703 1.10 (0.43–2.80) 0.061 1.15 (0.45–2.91) 0.059 1.13 (0.44–2.88) 0.046 0.98 (0.74–1.31) 0.500
Quality score
o10 6 269/467 1.43 (0.63–3.22) 0.201 0.88 (0.40–1.95) 0.270 1.13 (0.57–2.27) 0.342 1.43 (0.74–2.77) 0.002
X10 5 1,272/1,832 1.02 (0.61–1.71) 0.069 1.01 (0.63–1.60) 0.131 1.02 (0.62–1.67) 0.071 1.09 (0.85–1.39) 0.060
SCC 8 670/1,635 1.05 (0.62–1.80) 0.246 1.01 (0.66–1.54) 0.634 1.02 (0.65–1.60) 0.364 1.07 (0.80–1.43) 0.085
Ethnicity
Caucasian 7 628/1,397 1.12 (0.59–2.14) 0.171 0.98 (0.62–1.53) 0.542 1.04 (0.60–1.82) 0.265 1.14 (0.83–1.56) 0.094
Other3 1 42/238 0.86 (0.23–3.20) — 1.34 (0.36–4.97) — 1.06 (0.30–3.78) — 0.67 (0.34–1.29) —
Quality score
o10 4 160/268 1.27 (0.36–4.53) 0.108 0.96 (0.36–2.56) 0.321 1.08 (0.34–3.47) 0.147 1.26 (0.66–2.40) 0.141
X10 4 510/1,367 0.91 (0.57–1.47) 0.444 1.02 (0.63–1.66) 0.636 0.96 (0.60–1.52) 0.527 1.02 (0.72–1.45) 0.08
BCC 6 804/1,891 1.07 (0.64–1.79) 0.090 0.82 (0.47–1.42) 0.068 0.92 (0.59–1.45) 0.152 1.46 (0.95–2.25) o0.001
Ethnicity
Caucasian 4 509/1,188 1.12 (0.50–2.48) 0.130 0.65 (0.33–1.28) 0.240 0.75 (0.48–1.15) 0.466 1.95 (0.92–4.14) o0.001
Other3 2 295/703 1.11 (0.44–2.80) 0.066 1.09 (0.38–3.09) 0.038 1.11 (0.41–2.95) 0.04 1.04 (0.78–1.40) 0.720
Quality score
o10 1 21/59 2.50 (0.51–12.14) — 0.15 (0.02–0.90)4 — 0.68 (0.15–3.00) — 9.79 (3.13–30.60)4 —
X10 5 783/1,832 0.98 (0.58–1.67) 0.094 0.92 (0.57–1.49) 0.159 0.96 (0.58–1.60) 0.093 1.18 (0.86–1.62) 0.021
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; NMSC, nonmelanoma skin cancer; OR, odds ratio; SCC, squamous cell carcinoma.
1Number of comparisons.
2P-value of Q-test for heterogeneity test.
3All populations combined, except for Caucasian.
4Statistically significant results.
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tumor-suppressive effects, has been reported in skin cancer
(Benjamin and Ananthaswamy, 2007; Benjamin et al., 2008).
Furthermore, mutant TP53 of the Arg72 variant form is more
likely to inhibit downstream apoptotic pathways (Marin et al.,
2000). As has been reported, the presence of Arg72
in the mutant allele or preferential retention of Arg72 allele
in the tumoral tissue provides a selective growth advantage
to tumor cells during the stage of tumorigenesis (Tada et al.,
2001). Therefore, the contradictory effects of the two
polymorphic variants in wild-type and mutant TP53 may be
the reason that no impact of the TP53 genotype on the
susceptibility to any type of skin cancer was detected in our
meta-analysis. Still another possibility is that the influence of
the TP53 genotype might be masked by the presence of other,
as-yet unidentified, causal genes involved in skin cancer
development.
Some limitations of this meta-analysis should be addres-
sed. First, all the eligible studies were published papers
written in English cited by PubMed. It is possible that some
relevant published or unpublished studies written in English
or other languages that might meet the inclusion criteria were
missed. Hence, some inevitable publication bias might exist
in the results, although the funnel plots as well as Egger’s
linear regression tests indicated no remarkable publication
bias in the meta-analysis. Second, in the subgroup analyses
by ethnicity, only one study was conducted in Asians and
data concerning other ethnicities, such as African, were not
found. Thus, additional studies are warranted to evaluate the
effect of this functional polymorphism on skin cancer risk in
different ethnicities, especially in Asians and Africans. Third,
the lack of original data, including data on genotypes and
environmental risk factors, from the included studies limited
our further evaluation of potential gene–environment inter-
actions, especially the interaction between infection with
human papillomavirus and TP53 Arg72Pro polymorphism,
which was investigated in several studies (Dokianakis et al.,
2000; O’Connor et al., 2001; Cairey-Remonnay et al., 2002;
McGregor et al., 2002; Gustafsson et al., 2004; Queille et al.,
2007). However, unlike human papillomavirus infection in
cervical carcinoma, the role of this virus in the etiology of
skin cancer remains controversial (Sterling, 2005). Never-
theless, a more precise analysis should be conducted if
individual data are available.
Despite the limitations, the results of this meta-analysis
suggest that TP53 Arg72Pro polymorphism may have little
involvement in the pathogenesis of skin cancer, regardless
of type, including melanoma, SCC, and BCC. Nevertheless,
well-designed studies with large sample sizes are warranted
to confirm our findings.
MATERIALS AND METHODS
Publication search
We searched articles, using the search terms ‘‘p53’’ or ‘‘TP53’’,
‘‘polymorphism’’ or ‘‘variation’’, and ‘‘skin cancer’’ or ‘‘melanoma’’
or ‘‘non-melanoma’’ or ‘‘squamous cell carcinomas’’ or ‘‘basal cell
carcinomas’’, in the Medline database utilizing the PubMed engine,
with the last search updated on 20 March 2010. We evaluated all
associated publications to retrieve the most eligible literature. Their
reference lists were searched manually to identify other relevant
publications. Results were limited to English-language papers.
Inclusion and exclusion criteria
The following inclusion criteria were used in selecting literature
for further meta-analysis: (i) published in peer-reviewed journals,
(ii) about TP53 Arg72Pro polymorphism and risk of skin cancer,
and (iii) describing useful genotype frequencies. Major exclusion
criteria included (i) not being a case–control study, (ii) a control
population that included malignant tumor patients, and (iii)
duplication of a previous publication.
Data extraction
Two investigators (Jiang and Wang) reviewed and extracted
information from all eligible publications independently, according
to the inclusion and exclusion criteria listed above. In the case of a
conflict, an agreement was reached by discussion between the two
reviewers. The following characteristics were collected from each
study: first author’s surname, year of publication, country of origin,
ethnicity, source of case and control groups, specimens used for
assessment of the TP53 Arg72Pro genotype, tumor type, total
number of cases and controls, as well as numbers of cases and
controls with the Arg/Arg, Arg/Pro, or Pro/Pro genotype.
Quality score assessment
The quality of the studies was also independently assessed by the
same two reviewers according to the predefined scale for quality
assessment (Table 5). These scores were based on both traditional
epidemiological considerations and cancer genetic issues. Any
disagreement was resolved by discussion between the two
reviewers. Total scores ranged from 0 (worst) to 15 (best). Reports
scoring o10 were classified as ‘‘low quality’’, and those X10 as
‘‘high quality’’.
Statistical analysis
We first assessed Hardy–Weinberg equilibrium for each study using
the goodness-of-fit test (w2 or Fisher exact test) only in control groups.
Crude ORs with 95% CIs were used to assess the strength of
association between TP53 Arg72Pro polymorphism and risk of
overall and subtypes of skin cancer. The pooled ORs were performed
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Figure 1. Begg’s funnel plot of TP53 Arg72Pro polymorphism and skin
cancer risk for homozygote comparison (Arg/Arg vs. Pro/Pro). Each circle
represents a separate study for the indicated association, and its size is
proportional to the sample size of each study.
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according to the random-effects model (the DerSimonian and Laird
model) (DerSimonian and Laird, 1986) for a codominant model
(homozygote comparison: Arg/Arg vs. Pro/Pro, heterozygote compar-
ison: Arg/Pro vs. Pro/Pro), dominant model (Arg/ArgþArg/Pro vs. Pro/
Pro), and recessive model (Arg/Arg vs. Arg/Proþ Pro/Pro). Stratified
analyses were also performed by ethnicity (Caucasian and other
populations) and quality score of studies (o10 andX10). A w2-based
Q-test was performed to check the between-study heterogeneity
(Cochran, 1954). One-way sensitivity analyses were performed to
access the stability of the meta-analysis results (Tobias, 1999).
Potential publication bias was estimated using Egger’s linear regres-
sion test by visual inspection of the funnel plot. Po0.05 was
considered representative of statistically significant publication bias
(Egger et al., 1997). All statistical tests were performed with the STATA
software, version 10.0 (Stata Corporation, College Station, TX).
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